CLVS Clovis Oncology Inc.
20.76
-0.87 -4%
Previous Close
21.63
Open
21
Price To Book
4.69
Market Cap
1094297529
Shares
52,711,827
Volume
4,738,331
Short Ratio
Av. Daily Volume
3,382,789
NewsSee all news
- Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
- See what the IHS Markit Score report has to say about Clovis Oncology Inc.
- CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
- What’s the Market Opportunity for Zejula?
- Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
SEC filingsSee all SEC filings
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrollment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 initial data presented at ESMO - 44% ORR.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 ongoing.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Latest News
- Do Options Traders Know Something About Clovis (CLVS) Stock We Don't?
- See what the IHS Markit Score report has to say about Clovis Oncology Inc.
- CHMP Grants Positive Opinion for New Indication of Clovis Oncology’s Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
- What’s the Market Opportunity for Zejula?
- Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
- Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
- Biotech Stocks Beating the Market
- Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher
- Should You Avoid Clovis Oncology Inc (CLVS)?
- Could These Be the Next 2 Biotech Buyouts?
- TopGainers: AutoZone, Clovis, Restoration Hardware Sidestep Selloff
- Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8%
- Why Clovis Oncology Stock Rose 48% in November
- TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer
- Clovis Oncology Announces Positive Outcome in European Opposition Proceeding Related to Rubraca®
- Today's Research Reports on Trending Tickers: Clovis Oncology and Tesaro
- Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today
SEC Filings
- SC 13D - General statement of acquisition of beneficial ownership 181160873
- 10-Q - Quarterly report [Sections 13 or 15(d)] 181151352
- 8-K - Current report 181147007
- 8-K - Current report 181144799
- SC 13G - Statement of acquisition of beneficial ownership by individuals 181137969
- 8-K - Current report 181120374
- S-8 - Securities to be offered to employees in employee benefit plans 18988970
- 10-Q - Quarterly report [Sections 13 or 15(d)] 18987591
- 8-K - Current report 18984864
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18916639